Blood pressure (BP) measurements taken outside the routine office context may be a useful adjunct strategy to monitor BP. Community-based BP data can also provide estimates of the prevalence of elevated BP. We compared multiple readings taken on different days in pharmacies using an automated BpTRU device during a cardiovascular health programme targeting community-dwelling older adults. Mean systolic (S) and diastolic (D) BP values were compared over time using repeated measures analysis of variance for all participants with at least three separate sets of readings (n ¼ 317). BP variability was then examined among four subgroups based on report of antihypertensive medication or no treatment, and normal or elevated SBP at the initial visit (o or X140, or 130 if diabetes reported). Prevalence of elevated BP was compared across visits. Overall, mean SBP decreased between visits 1 and 2 (140.4 vs 137.1 mm Hg; Po0.001). Among participants with normal SBP at the initial visit, SBP did not vary significantly, whether or not antihypertensive treatment was reported. Those with initially elevated SBP experienced a significant decrease between visits 1 and 2, also regardless of treatment status. Prevalence of elevated BP decreased from visits 1 to 2 (55.8 vs 48.9%; P ¼ 0.026) and from visits 1 to 3 (55.8 vs 42.9%; Po0.001). Analyses of BP data from a communitybased programme using an accurate device showed that initial readings may inflate the population estimate of elevated BP. Findings suggest that more than one set of BP readings measured on different occasions are needed, particularly if the first set is elevated.
Introduction
Blood pressure (BP) measurements taken outside the routine office context may be a useful adjunct strategy to assess a patient's BP status. Older individuals in particular are at risk of developing hypertension, and may benefit from regular community-based monitoring to promote optimal prevention, detection and treatment of high BP. Programmes using an accurate BP measurement device in a community setting have potential to reach a larger segment of the population at risk, 1 and may help to identify individuals experiencing white-coat or masked hypertension during in-office measurement. 2 Community pharmacies in Canada are familiar, accessible environments for older adults to access BP monitoring; many visit regularly for prescription refills or shopping or to measure their BP with existing devices installed in stores. 1 Use of an automated device removes the effect of the observer in measuring and recording BP, such as terminal digit preference. 3, 4 Such devices can also minimize the potential effects of observer-subject interaction in the clinic setting. 5 The portable BpTRU (BpTRU Medical Devices, www.BpTRU.org) has been compared in clinical settings with auscultatory and ambulatory BP monitoring and shown to be an accurate means of BP determination. 6, 7 Its use in clinical practice can improve the accuracy of readings, 5, 8 particularly in cases where white-coat effect is suspected. 9 Employing validated, automated devices in out-of-office settings is intended to increase the availability and accuracy of BP measurements used in diagnosing and managing hypertension. 1, 10 From an epidemiological perspective, communitywide programmes can yield population-based data to guide initiatives for population-based chronic disease prevention and management strategies. Community-based BP measurements can provide estimates of the prevalence of elevated BP to direct efforts for improving detection and management of hypertension. Although more readings are generally better for diagnosis and management of high BP, the value of single or multiple community-based readings in estimating the prevalence of elevated BP in a population has not been well explored.
Materials and methods
We compared multiple BP measurements taken on different days in pharmacies using the BpTRU (model BPM-100Beta). The readings were collected during community-wide delivery of the Cardiovascular Health Awareness Program (CHAP), 10 a community-wide programme targeting communitydwelling older adults. CHAP includes peer-led risk assessment sessions held in community pharmacies over a 10-week period and seeks to reach as many older adult residents as possible through community-wide advertising and direct invitation by family physicians.
Volunteer peer health educators trained by a public health nurse and supported by a programme coordinator assisted participants to measure their BP and recorded cardiovascular risk factors on a standardized, computer-readable form. The pharmacy setting was generally well suited to the CHAP assessment activities. Tables and chairs and the BpTRU devices were provided by the programme. Pharmacy locations with limited space presented some challenges in setting up the assessment 'stations'. Programme staff and volunteers were conscious of the need to maintain attendees' privacy in busy areas.
At their first visit, participants were greeted and given an information sheet by a volunteer or the programme coordinator, before providing written, informed consent. At one of several assessment stations set up in the pharmacy, a volunteer explained how the BpTRU automated device worked and initiated completion of the cardiovascular risk profile form (Appendix A, available online), which allowed participants to rest for several minutes before their BP was measured. The full cardiovascular risk factor profile was completed at the first visit; the sections for participantidentifying data (name, date of birth, postal code), consent to feedback of results to the family physician and/or pharmacist and BP and pulse were completed at each subsequent visit. Volunteers were trained to ensure the correct seated posture, cuff size and placement and operation of the BP measurement device. Participants were encouraged not to converse during the assessment, which takes about 10 min. The BpTRU takes six measures at prespecified intervals, discards the first reading and averages the remaining readings. The time from the start of one reading to the next can be set at intervals of 1, 2, 3, 4 or 5 min; most studies have used 1 or 2 min 6,11 though some have used 5 min. 9 CHAP assessments used a 1-min interval.
The average BP result at each visit was recorded for the participant. With consent, the information was forwarded to the family physician at the end of the 10-week programme. Participants with systolic (S) BP X180 or diastolic (D) BP X110 mm Hg, confirmed by a re-assessment conducted by an oncall nurse, were referred the same day to their family physician or to urgent care. Participants with BP X140/90 mm Hg at the first visit were encouraged to return for another assessment on a different day.
Mean SBP and DBP values were compared over time using repeated measures analysis of variance (ANOVA) for all participants who attended at least three CHAP sessions on different days. A two-way ANOVA was conducted comparing SBP across three visits in four subgroups of patients (untreated and normotensive, treated and normotensive, untreated and elevated and treated and elevated). Patients were grouped based on reported use of prescribed antihypertensive medication or no treatment, and elevated or normal SBP at the initial visit. SBP was considered elevated if it was X140, or X130 mm Hg for participants reporting a diagnosis of diabetes. Changes in SBP within each group were examined using a 4 Â 3 ANOVA followed by four univariate ANOVAs. The analysis was repeated for participants who attended at least two CHAP sessions.
The prevalence of elevated SBP, DBP or either was compared between visits 1 and 2, 2 and 3 and 1 and 3, using McNemar's test. BP was considered elevated if SBP was X140 mm Hg or DBP was X90 mm Hg; X130/80 mm Hg was the threshold applied if diabetes was reported.
Results
Across the two communities, there were 4165 CHAP session visits by 2350 older adults responding to a direct invitation from their family physician or community-wide advertising. The average age of attendees was 70.9 (s.d. ¼ 10.8) years and 59.1% were women. Nearly half of participants (43.9%; 1031/2350) returned for a second assessment, 1012 of whom provided information about antihypertensive treatment. There were 317 participants who had at least three visits and 308 also provided information about antihypertensive treatment. Their mean age was 70.5±9.4 years, and 58.0% were women. By self-report, 58.7% (186/308) of these participants were currently on antihypertensive The mean SBP and DBP and 95% confidence intervals across three visits (n ¼ 317) are shown in Figure 1 . Overall, SBP decreased significantly between the initial visit and visit 2 (140.4 vs 137.1 mm Hg; Po0.001), whereas DBP did not change significantly across three visits.
The changes in SBP for four subgroups are shown in Figure 2 . There were no significant changes over time for individuals with normal SBP at the initial visit, whether or not antihypertensive treatment was reported. Individuals with elevated SBP at the initial visit experienced a significant decrease in SBP between the first and second visits, also regardless of treatment status (Po0.001 for both).
A significant decrease in mean SBP by the second visit (137. 4 
Discussion
Data from a community-wide programme to promote good cardiovascular health among older adults provided an opportunity to examine BP variability across assessments on different days in a nonclinical setting. Understanding patterns in BP measured in the community can inform estimates of the prevalence of undiagnosed or undertreated high BP in populations.
The programme was attended by approximately 30% of the total senior population in each community and the prevalence of elevated BP was high (42.5% at the initial visit). Previous implementations of the programme that included a chart audit in participating practices revealed that attendees are similar to non-attendees, suggesting that participants are representative of the larger population of senior residents in terms of cardiovascular risk factors. 12 In the analysis reported here, mean SBP measured in community pharmacies was significantly lower at the second visit. This trend suggests a possible 'programme effect' in which some individuals experience artificially elevated BP at the first programme encounter, analogous to the white-coat effect observed in clinical settings.
Further exploration of BP patterns in four subgroups, based on treatment status and initial SBP, showed that the overall drop in SBP after visit 1 was driven by individuals with elevated SBP at the first visit. The decrease was observed in both treated and untreated groups with a high SBP at the initial visit; Figure 2 Mean systolic blood pressure (BP) over time for four subgroups of participants based on systolic BP at the initial visit and report of antihypertensive treatment (n ¼ 308).
Blood pressure variability in the community T Karwalajtys et al the mean SBP was relatively stable from visit 2 to 3, although still elevated. Less fluctuation in SBP occurred among normotensive individuals, also regardless of treatment status. These findings suggest that the first community-based reading may be artificially high for individuals who have elevated BP that is undiagnosed or undertreated. The size of the overall difference in mean SBP between visits 1 and 2 is modest, varying 3.3 mm Hg in the group with three visits, and 3.5 mm Hg in the group with only two visits. However, among participants with elevated SBP at the initial visit, mean SBP decreased 9.7 mm Hg in the treated group and 8.0 mm Hg in the untreated group, a clinically important difference suggesting white-coat effect. Although we did not capture changes in drug or dose in the subgroup reporting antihypertensive treatment, the fact that assessment results were not fed back to physicians until the end of the 10-week programme period (excepting high-risk cases with BP4180/110) and the short intervals of the repeated measures are expected to minimize the effects of treatment changes. White-coat effects have been observed in pharmacy-based BP assessment in comparison to ambulatory monitoring. 13 There may be a subgroup of individuals that demonstrates a variation of the white-coat effect as a result of the clinical nature of BP measurement in the community pharmacy. Further research is needed to confirm this, with reference to domiciliary or ambulatory BP measurements. Measurement of BP at pharmacy sessions using the BpTRU appears to reflect patients' BP status more reliably than in-office readings; one of our previous studies incorporating patient chart review found that among individuals with elevated SBP (X140 mm Hg) in the office, the mean of the most recent office SBP was significantly higher than the mean SBP at the first pharmacy visit, while there was no difference for normotensives. 2 Given that overestimation of high BP can lead to overtreatment, and associated personal and health system burdens, multiple BP measurements are important to estimate the prevalence of hypertension in a population. Our analyses suggest that at least two sets of readings, obtained on different occasions, are required to provide a robust estimate of BP status across participants in a community programme. Although the BpTRU discards the first reading and reports the average of the subsequent five measurements taken at one sitting, mean BP results from the first pharmacy visit appear to be artificially high for a substantial number of participants. To counter this, the results of the first assessment could be discarded and the subsequent readings taken on different occasions averaged to estimate the population mean.
Several large trials and population-based surveys have omitted the first of multiple BP assessments taken on one occasion. For instance, before the Systolic Hypertension in the Elderly Program trial, individuals not on antihypertensive treatment with SBP X150 mm Hg on the initial reading using a mercury sphygmomanometer had their BP measured two more times, and the mean of the latter two readings were used to determine eligibility for the trial (SBP 160-219 mm Hg and DBP o100 mm Hg). 14 The Ontario Survey on the Prevalence of High Blood Pressure compared BP measured with the BpTRU vs a mercury sphygmomanometer in a random sample of 10% of survey participants, using the mean of the last three of four manual readings and the mean of the last five of six readings taken by the BpTRU. 15 The National Health and Nutrition Examination Survey excluded the first BP measurement and collected the average of up to three additional BP determinations by physicians at a single visit. 16 Our analyses respond to the epidemiological challenge of estimating the prevalence of hypertension. Our data suggest that at least two readings on different days are needed to accurately estimate the proportion of a population with elevated BP. We report the change in mean SBP over three visits, as each visit appears to add information, however the significant decrease in SBP from visit 1 to 2 held when the analysis was replicated for participants with two visits. Analyses of mean BP over time should be interpreted with some caution, however, as a portion of the variability may be attributable to differences in groups. Another analysis in this programme population showed that individuals who had elevated BP at the first visit or were taking antihypertensive medication were more likely to visit more than once. Regression towards the mean could also be a factor, but would be expected to apply equally to both treated and untreated groups.
Understanding variability in BP is also clinically important. Further research is needed to establish guidelines to assist physicians in using BP data from community programmes. Developing a protocol for use of accurate community-based BP readings is in keeping with established approaches to diagnosing hypertension using multiple readings over time. Physiological fluctuations in BP reflect the complex interaction between genetic factors, environmental stimulation and cardiovascular control mechanisms; and measurement error introduces additional variability in BP over time. In our study, the decrease between visits 1 and 2 appears robust and clinically important. Other large studies, including the Australian National BP Study 17 and the British National Research Council Trial, 18 have found that BP measured under identical conditions tends to be higher at the first assessment in a new environment and to decrease with repeat visits to the same venue. In contrast to these studies, where BP was measured manually by a physician or nurse and is thus subject to observer error, changes in BP measured using the BpTRU in a community setting could arguably provide a more reliable estimate of the difference.
Sustainable programmes that include accurate, automated BP assessment in a familiar environment can provide valuable information to help diagnose and manage high BP in individuals, and also to describe the prevalence of hypertension in populations. Community-based BP assessment can support the detection of individuals with undiagnosed or undertreated hypertension; however, multiple readings on separate occasions are needed to estimate BP status, especially if the first set is elevated. Further work is needed to determine the extent of artificial elevation of BP in a community context compared to that found in clinical settings and to better understand possible temporary effects related to the first programme encounter.
